Developing
Biosimilars and CAR-T Cell pharmaceuticals
Driving significant cost reductions of key treatments for Leukemia, Multiple Sclerosis, age related vision loss and many other.
What is a Biosimilar medicine?
A medicine developed to be similar to an
already existing and approved medicine
which patent has expired and therefore can
be sold at significantly lower prices.
Biosimilars are driven by a social agenda to
make key life-saving drugs affordable to the
general public.
Biosimilars Vs. Generic medicines
Generic medicines are also developed as copies of pharmaceuticals with expired patents.
Unlike Biosimilars, Generic drugs are based on Chemical or Small Molecules based active ingredients which are easy to synthesize and formulate with vast knowhow available in public domain.
Unlike Biosimilars, Generic drugs are based on Chemical or Small Molecules based active ingredients which are easy to synthesize and formulate with vast knowhow available in public domain.
Biosimilars are based on Large and Complex Molecules from Living Organisms (instead of chemicals) and cannot readily be synthesized by chemical means.
Such medicines (known as Biological drugs) are developed under significant trade secrets, have very little information in public domain and require significant knowhow and scientific skill to achieve successful replication.
Such medicines (known as Biological drugs) are developed under significant trade secrets, have very little information in public domain and require significant knowhow and scientific skill to achieve successful replication.
Biological drugs are extremely expensive for patients due to high development and manufacturing costs and can reach hundreds of thousands of dollars per specific treatment for one patient.
Due to the high costs of Biological drugs:
- 20% of patients choose to skip a dose every other month.
- Cancer patients are 2.5 times more likely to file for bankruptcy.
- 30% of patients are completely drained from their savings.
- Millions cannot afford even to start treatment at any.
level Fred Hutchinson, Cancer Research Center – Seattle USA
CAR-T Cell Therapy
A novel scientific approach focused on “programming” patient’s own immune cells to identify and destroy cancer cells
First implementation of CAR-T wasin identification and destruction of Leukemia cancer cells.
2017, Emily Whitehead (USA), was the first Leukemia patient treated with CAR-T cell therapy. She was completely cured with total remission.
2017, Emily Whitehead (USA), was the first Leukemia patient treated with CAR-T cell therapy. She was completely cured with total remission.
October 16,2018
BIOCURE ANNOUNCED a BREAKTHROUGH PRE-CLINICAL TRIAL RESULTS FOR CAR-T CELLS TREATMENT OF ACUTE LEUKEMIA
Trial results demonstrated zero toxicity of the reengineered BioCure CAR-T Cells within 7 and 28 days from their injection into mice.
BIOCURE ANNOUNCED a BREAKTHROUGH PRE-CLINICAL TRIAL RESULTS FOR CAR-T CELLS TREATMENT OF ACUTE LEUKEMIA
Trial results demonstrated zero toxicity of the reengineered BioCure CAR-T Cells within 7 and 28 days from their injection into mice.
CAR-T Cells therapy represent the most advanced scientific methods and biggest hope for millions of people suffering from cancer
Our Social Agenda
Affordable Key
Pharmaceuticals
Patent expiration of major Biological drugs
during the coming years creates an early
market opportunities for Biosimilars.
Our agenda is to provide as many Biosimilar
products as possible to leverage BioCure
unique scientific knowhow and skills to
drive social equality via affordable
medicines.
Products
Chronic Lymphocytic Leukemia
CAR-T Cell Therapy
Clinical
2021
Commercial
2022
Multiple Sclerosis (MS)
Interferon Beta
Clinical
2022
Commercial
2023
Age related vision loss
Ranibizumab
Clinical
2022
Commercial
2023
Chemotherapy Effects
Treatment
PEG-Filgrastim
Clinical
2023
Commercial
2024
